Cargando…

The Effect of Tumor Microenvironment on Autophagy and Sensitivity to Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma

Lung cancer is the top cancer killer worldwide. Tyrosine kinase inhibitors (TKIs), for example erlotinib, are commonly used to target epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (ADC). Autophagy is a cellular response to stress, serving as a protective mechanism during antica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuan-Yuan, Lam, Sze-Kwan, Zheng, Chun-Yan, Ho, James Chung-Man
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Short Research Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349879/ https://www.ncbi.nlm.nih.gov/pubmed/25767609 http://dx.doi.org/10.7150/jca.11187

Ejemplares similares

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
por: Kirchner, M., et al.
Publicado: (2021)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma
por: Dahse, R, et al.
Publicado: (2008)

Prevalence of EGFR Mutations and Clinico-Pathological Characteristics of Chilean Lung Cancer Patients
por: Gejman, Roger, et al.
Publicado: (2019)

Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models
por: Lam, Sze-Kwan, et al.
Publicado: (2018)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
por: Tseng, Chien-Hua, et al.
Publicado: (2017)

Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
por: Kim, Eun Young, et al.
Publicado: (2019)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo
por: Hu, Xiangxiang, et al.
Publicado: (2017)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma
por: Qiu, Xiaowei, et al.
Publicado: (2018)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR unusual mutation status in lung adenocarcinomas
por: Alarcão, Ana, et al.
Publicado: (2010)

No Mutations of Lysophosphatidic Acid Receptor Genes in Lung Adenocarcinomas Induced by N-Nitrosobis(2-hydroxypropyl)amine in Rats
por: Wakabayashi, Naoko, et al.
Publicado: (2010)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
por: Li, Teng, et al.
Publicado: (2021)

Emerging EGFR-Mutated Subclones in a Patient With Metastatic ALK-Rearranged Lung Adenocarcinoma Treated With ALK-Targeted Therapy: A Case Report
por: Leung, Jackson Ka Chun, et al.
Publicado: (2023)

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
por: Kim, Eun Young, et al.
Publicado: (2018)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Detected EGFR mutation in cerebrospinal fluid of lung adenocarcinoma patients with meningeal metastasis
por: Rong, Jiang, et al.
Publicado: (2016)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Lymphocytes are less sensitive to autophagy than monocytes during fasting and exercise conditions
por: Kröpfl, Julia M., et al.
Publicado: (2022)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
por: Berger, Alice H., et al.
Publicado: (2013)

Expression and functional characterization of the putative protein 8b of the severe acute respiratory syndrome‐associated coronavirus
por: Law, Pui Ying Peggy, et al.
Publicado: (2006)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Stratifin accelerates progression of lung adenocarcinoma at an early stage
por: Shiba-Ishii, Aya, et al.
Publicado: (2015)

Effect of icotinib on advanced lung adenocarcinoma patients with sensitive EGFR mutation detected in ctDNA by ddPCR
por: Chen, Hua-Fei, et al.
Publicado: (2019)

A Novel Technique to Detect EGFR Mutations in Lung Cancer
por: Liu, Yuanbin, et al.
Publicado: (2016)

Uncovering mediators of collagen degradation in the tumor microenvironment
por: Thorseth, Marie-Louise, et al.
Publicado: (2022)

The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
por: Boeckx, Carolien, et al.
Publicado: (2015)

Model for predicting EGFR mutation status in lung cancer
por: Nguyen Ho, Lam, et al.
Publicado: (2019)

Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)
por: Naka, Go, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bvvusm2ncuhk26ma6t2hipc6vg